<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02751177</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A01272-47</org_study_id>
    <nct_id>NCT02751177</nct_id>
  </id_info>
  <brief_title>Detection of KRAS, NRAS et BRAF Mutations in Plasma Circulating DNA From Patients With Metastatic Colorectal Cancer</brief_title>
  <acronym>ColoBEAM</acronym>
  <official_title>Multicenter Prospective Study Comparing KRAS, NRAS and BRAF Mutation Testing Using OncoBEAM Technique in Plasma vs Conventional Techniques in Formalin Fixed Paraffin Embedded Tissues</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RAS genotyping is mandatory for the prescription of anti-EGFR (epidermal growth factor
      receptor) therapies in patients with metastatic colorectal cancer. The standard genotyping is
      assessed on formalin-fixed paraffin embedded tumour tissue. This study compares RAS and BRAF
      genotyping results achieved in analyzing circulating plasma DNA using OncoBEAM™ technique
      with those achieved using the standard genotyping techniques and formalin-fixed paraffin
      embedded samples.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be proposed to all patients with a metastatic colorectal cancer.

      Study information will be given to the patient during a routine medical examination. The
      patient will be included after checking inclusion criteria and signature of the informed
      consent form

      Blood sampling (30 ml) will be performed before the initiation of the first line metastatic
      chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 25, 2016</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>KRAS, NRAS et BRAF mutational status</measure>
    <time_frame>up to 6 months</time_frame>
    <description>Compare the results of KRAS (exons 2, 3 et 4), NRAS (exons 2, 3 et 4) and BRAF (V600) genes genotyping using OncoBeam technique in blood samples with results achieved routinely by the molecular genetics platforms of the recruiting centers.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">236</enrollment>
  <condition>Colorectal Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>OncoBEAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KRAS, NRAS and BRAF mutations will be analyzed in circulating plasma DNA using ONCOBEAM technique.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA</intervention_name>
    <description>Mutation in plasma DNA vs tumor tissue</description>
    <arm_group_label>OncoBEAM</arm_group_label>
    <other_name>metastatic colorectal cancer</other_name>
    <other_name>OncoBEAM</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult subjects with newly diagnosed, anti EGFR treatment naïve metastatic colorectal
             cancer

          -  Standard of Care RAS/RAF tests performed on FFPE tumor sample as part of routine

          -  Patient information and written informed consent form signed

          -  Patient must be affiliated to a social security system

          -  Age : 18 years and older

        Exclusion Criteria:

          -  Patient bearing non-metastatic colorectal cancer

          -  Patient with local relapse only

          -  Patient with exclusive nodal metastases

          -  Patient whose health contraindicates a 30 ml blood sample

          -  Blood transfusion within 1 week prior blood collection

          -  Patient having received any chemotherapy or / and radiotherapy within 15 days prior to
             blood collection

          -  History of another primary cancer within the last 5 years, with the exception of
             non-melanomatous skin cancer and carcinoma in situ of the cervix

          -  Persons deprived of liberty or under supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MERLIN JEAN LOUIS</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>HARLE ALEXANDRE</last_name>
    <role>Study Chair</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>GAVOILLE CELINE, oncologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CH Auxerre</name>
      <address>
        <city>Auxerre</city>
        <zip>89000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Besançon-Hopital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Chalon Sur Saône-William Morey</name>
      <address>
        <city>Chalon Sur Saône</city>
        <zip>71 321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Belle-Isle-Metz</name>
      <address>
        <city>Metz</city>
        <zip>54045</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de Gentilly</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Reims-Hôpital Robert Debré</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique Courlancy Reims</name>
      <address>
        <city>Reims</city>
        <zip>51100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Stauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>KRAS gene mutation</keyword>
  <keyword>NRAS gene mutation</keyword>
  <keyword>BRAF gene mutation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

